Last reviewed:
People with HIV may be eligible for a GLP-1 medicine under the same product-specific indications as other patients. HIV alone does not rule it out. The choice depends on your health, full medication list and monitoring plan. Some ART combinations have no important interaction expected, but the evidence is often limited, and oral rilpivirine warrants additional attention.[1][2][3][16]
The drugs, and why the pharmacology is reassuring
Examples include semaglutide, a GLP-1 receptor agonist, and tirzepatide, a dual GIP/GLP-1 receptor agonist. Brands and formulations have different indications and dosing. Wegovy now includes oral tablets and injections; FDA approved Wegovy HD 7.2mg injections for eligible adults in March 2026. These are prescription treatments that require gradual dose escalation, not interchangeable starting doses.[17][12][9]
These drugs are broken down through peptide pathways rather than the CYP450 pathway involved in many ART interactions. Liverpool lists no clinically significant interaction expected for semaglutide with FTC/TAF and for tirzepatide with BIC/FTC/TAF. Both entries explicitly say coadministration has not been studied and grade the evidence as very low. That is a prediction for those combinations, not proof from trials testing every HIV regimen.[2][3]
Slower gastric emptying can affect oral medicines, and Liverpool also flags a possible absorption issue with oral rilpivirine because of effects on gastric secretion. It advises considering viral-load monitoring after semaglutide is started. Ask a pharmacist to plan timing for the actual products you take; do not assume the Biktarvy prediction applies to rilpivirine.[16] Oral semaglutide also has its own fasting and timing requirements. For Wegovy tablets, the label requires at least 30minutes before food, beverages or other oral medicines.[9][2][3]
Why this question matters specifically for people living with HIV
Weight gain is a documented feature of modern ART. The federal guidelines state that weight gain occurs with nearly all regimens but is “most pronounced with integrase strand transfer inhibitors (INSTIs), especially bictegravir and dolutegravir, and the nucleotide reverse transcriptase inhibitor (NRTI) tenofovir alafenamide (TAF),” and that pooled data from eight randomized trials found about 13% of people with HIV gain more than 10% of body weight in the first year[1]. Populations with greater ART-associated gain include female sex, older age, Black race or African descent, and greater HIV disease severity[1].
The primary ADVANCE report gives mean weight gains at 96 weeks of 7.1 kg with DTG/TAF/FTC, 4.3 kg with DTG/TDF/FTC and 2.3 kg with EFV/TDF/FTC, with greater gains among women. These are group averages from that South African trial, not a forecast for an individual. NIH advises continuing effective ART and addressing weight as part of care.[8][1]
Cardiometabolic stakes: why weight deserves attention
The federal guidelines cite the Veterans Aging Cohort Study finding each 5-pound gain associated with a 14% greater diabetes risk in people with HIV versus 8% in people without HIV, and the D:A:D cohort showing an 18%–20% increased relative cardiovascular-disease risk per 1.0 kg/m² BMI increase among people with HIV who started ART at normal weight — versus 4%–5% per unit in a comparable Finnish cohort without HIV[1]. ACTG cohort data link greater than 10% weight gain within a year of starting ART to higher risk of type 2 diabetes, metabolic syndrome, and cardiometabolic events[1].[1] These are associations from different observational cohorts, not a matched experiment showing how the same weight gain affects any two individuals.[1]
In its April 2023 announcement of the interim REPRIEVE results, NIH reported that the trial enrolled 7,769 people with HIV aged 40–75 on ART, with low-to-moderate traditional cardiovascular risk. Pitavastatin 4 mg daily reduced major cardiovascular events by 35% relative to placebo at that analysis. This was a statin trial, not a test of GLP-1 therapy.[7]
What the HIV-specific GLP-1 evidence actually shows
A randomized trial published in 2024 enrolled 108 adults with controlled HIV, BMI at least 25 and HIV-associated lipohypertrophy, without diabetes. Treatment lasted 32 weeks: eight weeks of dose escalation followed by 24 weeks at semaglutide 1.0 mg weekly or placebo. Estimated weight loss was 10.4%; abdominal visceral fat fell 30.6%, abdominal subcutaneous fat 11.2% and total body fat 18.9%. One participant had a severe lipase elevation and two had cholelithiasis. Limb-fat loss warrants attention in someone with lipoatrophy; the estimated lean-mass reduction was not statistically significant.[1][4][10]
SLIM LIVER was a 24-week, open-label study without a comparison group. Of 51 participants, 49 were included in the per-protocol analysis. Semaglutide titrated to 1.0 mg weekly was associated with improved liver fat and metabolic measures and average weight loss of 8.1%.[18] A separate analysis found reduced psoas-muscle volume without a significant decline in measured physical function.[19] In the observational CNICS cohort of 222 people with HIV, estimated weight loss at one year was 6.47 kg. HbA1c fell 1.07 percentage points among 157 participants with follow-up HbA1c data. Weight loss did not differ significantly by integrase-inhibitor use; this was not a randomized comparison.[6][5][1]
Safety, monitoring, and the guideline position
NIH’s September 2025 guidance advises using current general-population indications and prescribing information. The small HIV trials it summarizes used 1.0 mg semaglutide weekly and do not establish every dose’s long-term safety in people with HIV. Its older statement that 2.4 mg was the maximum obesity dose predates the March 2026 Wegovy HD approval. Use the current label and an individualized plan.[17][1]
Nausea, vomiting, diarrhea, constipation and abdominal discomfort are common. Product labels also address pancreatitis, gallbladder disease and dehydration-related kidney injury. Semaglutide and tirzepatide are contraindicated with a personal or family history of medullary thyroid carcinoma or MEN 2; severe gastroparesis also matters. Your clinician should review these risks, other medicines and any pregnancy plans before prescribing. Titrate according to the actual product label and tolerability.[12][9][11]
For injections, follow the product’s instructions and rotate sites. Report persistent or severe reactions. Tirzepatide can reduce the effectiveness of oral hormonal contraception: its label advises a non-oral method or an added barrier method for four weeks after starting and four weeks after each dose increase. For weight management, discuss pregnancy planning in advance; the Wegovy label calls for stopping at least two months before a planned pregnancy.[9][12]
Muscle health deserves attention during weight loss. The HIV trial did not prove a significant lean-mass loss, and a smaller psoas volume is not the same as loss of strength or function. Ask the care team about adequate nutrition, suitable resistance exercise and monitoring if you have frailty, lipoatrophy or unintentional weight loss.[10][19][5]
What to ask your HIV provider
Bring three things to the appointment.
Bring your ART regimen and all other medicines, including contraception and supplements. Explain the condition you hope to treat: having HIV, prediabetes or fatty liver does not automatically meet a particular product’s approved indication or your insurer’s criteria. Ask about viral-load checks, glucose monitoring when relevant, nutrition and a plan for side effects. Confirm the exact product, formulation and coverage before starting.[9][14][2][13][1][5]
Florida: coverage, cost, and compounded semaglutide
Coverage and cost vary by indication, product and plan. KFF’s June 2024 analysis of 2024 federal Marketplace formularies found Wegovy coverage in 1% of plans versus 82% for Ozempic. Those historical national figures are not a 2026 Florida coverage estimate or a person’s out-of-pocket price. Check your current formulary and ask the insurer about prior authorization, exceptions and appeals.[14][13]
For a Florida Marketplace plan, use the insurer’s current drug list and your Summary of Benefits and Coverage, and call the plan with the exact prescription. A statewide HIV mortality ranking cannot determine whether a GLP-1 medicine is appropriate for you.[14]
Compounded products are not FDA-approved substitutes. In its April 1, 2026 update, FDA says semaglutide and tirzepatide are not on its shortage or 503B bulks lists and explains restrictions on routine copies of approved products. It also describes patient-specific exceptions under 503A when a prescriber documents a significant difference. Adding vitamin B12 does not automatically create an exception, and limited enforcement discretion is not FDA approval. Ask the prescriber and pharmacist why a compounded product is needed and check current FDA guidance.[15]
Related questions
Will a GLP-1 make my HIV medication stop working?
An important interaction is not expected for some combinations, including tirzepatide with Biktarvy, but Liverpool grades that prediction as very-low-quality evidence. Oral rilpivirine combinations can need additional monitoring. Have your pharmacist check the exact GLP-1 product and full ART regimen.[2][3][16]
Does it still work if my weight gain came from my ART?
Weight loss was observed among semaglutide users taking integrase inhibitors in the 222-person CNICS cohort. The estimated loss did not differ significantly from that in people not taking an integrase inhibitor. This observational result does not guarantee the same response for everyone.[6]
Should I be worried about losing muscle?
Discuss muscle and nutrition monitoring. In the randomized HIV trial, estimated lean-mass loss was not statistically significant. SLIM LIVER found reduced psoas-muscle volume without significant decline in measured physical function. These measures are not interchangeable, and longer-term evidence remains limited.[10][19]
Is compounded semaglutide from a telehealth service a safe shortcut?
Compounded medicines are not FDA-approved. FDA’s current statement describes restrictions after shortage resolution and specific conditions for lawful compounding; it does not ban every patient-specific preparation or guarantee its safety. Ask why an approved product cannot meet your needs and review current FDA guidance with the prescriber and pharmacist.[15]
Related from RiseUpToHIV
References & Sources
- Clinicalinfo.HIV.gov — Weight Gain in People With Treated HIV (Adult and Adolescent ARV Guidelines). Federal panel guidance on GLP-1/GIP receptor agonists, ART-associated weight gain, cardiometabolic risk, and HIV-specific trial summaries. ↩ ↩ ↩ ↩ ↩ ↩ ↩ ↩ ↩ ↩ ↩ ↩ ↩
- Liverpool HIV Drug Interactions — Semaglutide + FTC/TAF. Metabolism by neutral endopeptidase, “Very Low” evidence grading, gastric-emptying note, and the Rybelsus 30-minute dosing rule. ↩ ↩ ↩ ↩ ↩ ↩ ↩ ↩ ↩
- Liverpool HIV Drug Interactions — Tirzepatide + BIC/FTC/TAF. “No Interaction Expected” rating with Biktarvy components; metabolism by proteolytic cleavage. ↩ ↩ ↩ ↩ ↩ ↩ ↩
- Eckard et al. (2024) — Primary randomized trial:108 participants,32 weeks including8-week titration; body composition and adverse events. Source. ↩
- ACTG — CROI 2024: SLIM LIVER (A5371) results. Semaglutide 1.0 mg in 49 adults with HIV and steatotic liver disease; liver fat, weight, A1C, and muscle-volume findings. ↩ ↩ ↩
- CNICS cohort — Weight loss associated with semaglutide among people with HIV. Real-world one-year outcomes in 222 people with HIV, with and without INSTI use. ↩ ↩ ↩
- NIH — REPRIEVE: daily statin reduces cardiovascular risk in people with HIV. 7,769 participants; 35% reduction in major adverse cardiovascular events with pitavastatin. ↩
- Venter et al. (2020) — ADVANCE week96 primary trial report; overall mean weight gains by randomized regimen. Source. ↩↩
- FDA — WEGOVY prescribing information, June2026: indications, oral and injectable forms, dosing and safety. Source. ↩↩ ↩ ↩ ↩
- Eckard et al. (2024) — Primary trial discussion and Table2: limb-fat reduction; lean-mass and psoas effects were not statistically significant. Source. ↩ ↩ ↩
- FDA — WEGOVY prescribing information: gradual escalation and individualized tolerability; study doses are not universal maintenance recommendations. Source. ↩
- Lilly — ZEPBOUND prescribing information, August2026: indications, injection instructions, warnings and contraception precautions. Source. ↩↩↩ ↩
- KFF (June12,2024) — Original analysis of 2024 federal Marketplace formularies; historical coverage, not current Florida plan probabilities. Source. ↩↩↩
- HealthCare.gov — How to verify prescription coverage, request exceptions and appeal denials. Source. ↩ ↩ ↩
- FDA — FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize. Shortage-list status, end of enforcement discretion (503B on May 22, 2025), and the April 1, 2026 update on compounded copies. ↩ ↩ ↩ ↩
- Liverpool HIV Interactions — Semaglutide with oral RPV/FTC/TAF: potential interaction; very-low-quality evidence; consider virologic monitoring. Source. Checked September 21, 2026. ↩ ↩ ↩
- FDA (March19,2026) — Approval of Wegovy HD 7.2mg for weight management in eligible adults. Source. Checked September 21, 2026. ↩ ↩
- Lake et al. (2024) — SLIM LIVER primary publication:51 enrolled,49 in per-protocol analysis;24-week single-arm pilot. Source. Checked September 21, 2026. ↩
- SLIM LIVER primary muscle analysis —47 participants with paired MRI/function outcomes at24weeks; muscle volume and physical function are different outcomes. Source. Checked September 21, 2026. ↩ ↩ ↩
Community publications like POZ, Positively Aware, and TheBody inform framing and lived-experience context on RiseUpToHIV. Every clinical, epidemiological, or public-health claim above is anchored to a primary source.